Curida was established in 2015 and is headquartered in Oslo, Norway, Curida Holding includes Curida AS, Curida Diatec AS and Ås Produksjonslab AS, and is an integrated Contract Development and Manufacturing Organization (“CDMO”) and offers contract development and manufacturing solutions to European pharmaceutical and biotech companies globally. Curida focuses on aseptic and non-aseptic liquid manufacturing and specializes in blow-fill-seal (“BFS”) and nasal spray technologies to serve the Small Molecules pharmaceutical and medical device market. For biologics, Curida offers upstream – and downstream processing of monoclonal antibodies for in-vitro diagnostics (“IVD”). Curida’s customer base ranges from small to medium-sized pharmaceutical and biotech companies, delivering solutions in drug development and GMP manufacturing globally.